- Home
- PAVM vs BYSI Comparison
PAVM vs BYSI Comparison
Compare PAVM & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | BYSI |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | 41 | 44 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.1M | 35.8M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | PAVM | BYSI |
|---|---|---|
| Price | $5.11 | $0.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $65.00 | N/A |
| AVG Volume (30 Days) | 8.6K | ★ 27.8K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $603.94 | N/A |
| Revenue Next Year | $33.16 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.87 |
| 52 Week High | $28.44 | $2.44 |
Technical Indicators
Market Signals| Indicator | PAVM | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 44.60 | 23.09 |
| Support Level | $4.45 | N/A |
| Resistance Level | $6.56 | $1.60 |
| Average True Range (ATR) | 0.46 | 0.09 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 37.46 | 0.00 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.